Current agents in development for treating behavioral and psychological symptoms associated with dementia
Abstract
Behavioral and psychological symptoms associated with dementia are highly prevalent and are associated with an increased risk of institutionalization and mortality. Current pharmacological treatments for these symptoms include cholinesterase inhibitors, antipsychotics, and selective serotonin reuptake inhibitors. When used for treating behavioral and psychological symptoms associated with dementia, they are associated with limited efficacy and/or serious adverse events. As such, there has been extensive research into novel agents with varying mechanisms of action targeting behavioral and psychological symptoms associated with dementia. In this article, we present the results of a comprehensive literature search and review that evaluates current agents that have completed or are currently in clinical trials for treating behavioral and psychological symptoms associated with dementia as a primary outcome. We highlight novel agents from miscellaneous drug classes, such as dextromethorphan/quinidine, bupropion/dextromethorphan, lumateperone, deudextromethorphan/quinidine, methylphenidate and scyllo-inositol, and drugs from various therapeutic classes (including atypical antipsychotics, selective serotonin reuptake inhibitors, and cannabinoids) that have demonstrated promising results and were generally well tolerated. Future research with large appropriately powered studies using validated outcome measures for behavioral and psychological symptoms associated with dementia should be conducted to further establish the clinical utility of these agents.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
EVP-6124 has a central role in regulating the release of various neurotransmitters.
“EVP-6124, an antagonist of 5-HT3 receptor and a agonist of 7 nicotinic acetylcholine receptor a has a central role in regulating the release of various neurotransmitters (Ahmed et al., 2019).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Ahmed et al., 2019
EVP-6124 is an antagonist of the 5-HT3 receptor and an agonist of the α7 nicotinic acetylcholine receptor.
“EVP-6124, an antagonist of 5-HT3 receptor and a agonist of 7 nicotinic acetylcholine receptor a has a central role in regulating the release of various neurotransmitters (Ahmed et al., 2019).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Ahmed et al., 2019
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267 · see citing works
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010 · see citing works
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589 · see citing works
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · see citing works
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578 · see citing works
Dementia: a public health priority
Acosta, D. M., Krishnamoorthy, E. S., Wortmann, M., Prince, M. J., & Saxena, S. (2012) · Cited by 1,955 · see citing works
Family caregivers of people with dementia
Brodaty, H., & Donkin, M. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/hbrodaty · Cited by 1,644 · see citing works
A Description of Agitation in a Nursing Home
Cohen-mansfield, J., Marx, M. S., & Rosenthal, A. S. (1989) · Journal of Gerontology · doi:10.1093/geronj/44.3.m77 · Cited by 1,349 · see citing works
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247 · see citing works
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,200 · see citing works
Family caregivers of people with dementia.
Brodaty, H., & Donkin, M. (2009) · PubMed · Cited by 981 · see citing works
Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Steinberg, M., Shao, H., Zandi, P. P., Lyketsos, C. G., Welsh-Bohmer, K. A., Norton, M. C., Breitner, J. C. S., Steffens, D. C., & Tschanz, J. T. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1858 · Cited by 743 · see citing works
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · see citing works
Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
Ballard, C. G., Waite, J., & Birks, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003476.pub2 · Cited by 528 · see citing works
Fleischhacker, W. W., & Brooks, D. J. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6020-6 · Cited by 439 · see citing works
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423 · see citing works
Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422 · see citing works
Pollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A. J., Marin, R. S., Jacob, N. J., Huber, K., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 329 · see citing works
Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.027 · Cited by 305 · see citing works
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O'Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 291 · see citing works
Vigen, C. L. P., Mack, W. J., Keefe, R. S. E., Sano, M. C., Sultzer, D. L., Stroup, T. S., Dagerman, K., Hsiao, J., Lebowitz, B. D., Lyketsos, C. G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.08121844 · Cited by 281 · see citing works
The history of lithium therapy
Shorter, E. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00706.x · Cited by 276 · see citing works
Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses
Tampi, R. R., Tampi, D. J., Balachandran, S., & Srinivasan, S. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316658463 · Cited by 267 · see citing works
McLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P., & Fraser, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m906994199 · Cited by 265 · see citing works
Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Onyango, I. G., Dennis, J., & Khan, S. M. (2016) · Aging and Disease · doi:10.14336/ad.2015.1007 · Cited by 260 · see citing works
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · see citing works
Managing Your Own Mood Lability: Use of Mood Stabilizers and Antipsychotics in Pregnancy
Wichman, C. L. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0646-1 · Cited by 258 · see citing works
A review of the role of serotonin receptors in psychiatric disorders
Naughton, M., Mulrooney, J. B., & Leonard, B. E. (2000) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/1099-1077(200008)15:6 · Cited by 258 · see citing works
Pollock, B. G., Mulsant, B. H., Rosen, J., Mazumdar, S., Blakesley, R. E., Houck, P. R., & Huber, K. A. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180cc1ff5 · Cited by 257 · see citing works
The contribution of neuropsychiatric symptoms to the cost of dementia care
Herrmann, N., Lanctôt, K. L., Sambrook, R., Lesnikova, N., Hébert, R., McCracken, P., Robillard, A., & Nguyen, E. H. L. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1594 · Cited by 232 · see citing works
Trillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., Dang, V., Sanchez, M. M., Miguel, Z. D., Ashford, J. W., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.008 · Cited by 224 · see citing works
Stahl, S. M. (2016) · CNS Spectrums · doi:10.1017/s1092852916000407 · Cited by 221 · see citing works
The Pittsburgh Agitation Scale: A User‐Friendly Instrument for Rating Agitation in Dementia Patients
Rosen, J., Burgio, L. D., Kollar, M., Cain, M., Allison, M. G., Fogleman, M., Michael, M., & Zubenko, G. S. (1994) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199400210-00008 · Cited by 215 · see citing works
Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., Raskind, M. A., & Peskind, E. R. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ab8c61 · Cited by 210 · see citing works
Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns
Steinberg, M., & Lyketsos, C. G. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12030342 · Cited by 209 · see citing works
Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209 · see citing works
Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant
Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316629071 · Cited by 198 · see citing works
Helmes, E., Csapo, K. G., & Short, J.-A. (1987) · Journal of Gerontology · doi:10.1093/geronj/42.4.395 · Cited by 197 · see citing works
Ballard, C. G., Bannister, C., Khan, Z., Cummings, J. L., Demos, G., Coate, B., Youakim, J. M., Owen, R., Stankovic, S., Tomkinson, E. B., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30039-5 · Cited by 192 · see citing works
Rosenberg, P. B., Lanctôt, K. L., Drye, L. T., Herrmann, N., Scherer, R. W., Bachman, D. L., Mintzer, J. E., & ADMET investigators (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08099 · Cited by 191 · see citing works
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Taylor, C. P., Traynelis, S. F., Siffert, J. O., Pope, L. E., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.010 · Cited by 188 · see citing works
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia
van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R., Kramers, C., Feuth, T. B., Rosenberg, P. B., van der Marck, M. A., & Rikkert, M. G. M. O. (2015) · Neurology · doi:10.1212/wnl.0000000000001675 · Cited by 166 · see citing works
Motoi, Y., Shimada, K., Ishiguro, K., & Hattori, N. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500056q · Cited by 155 · see citing works
Bipolar disorder and mechanisms of action of mood stabilizers
Rapoport, S. I., Basselin, M., Kim, H., & Rao, J. S. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.06.003 · Cited by 155 · see citing works
Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia
Lanctôt, K. L., Herrmann, N., & Mazzotta, P. (2001) · Journal of Neuropsychiatry · doi:10.1176/jnp.13.1.5 · Cited by 153 · see citing works
Wang, J., Yu, J., Wang, H.-F., Meng, X., Wang, C., Tan, C., & Tan, L. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308112 · Cited by 151 · see citing works
The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease
Mitchell, R., Herrmann, N., & Lanctôt, K. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00161.x · Cited by 141 · see citing works
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141 · see citing works
Lithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140 · see citing works
The NICE ADHD health technology assessment: A review and critique
Schlander, M. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-1 · Cited by 138 · see citing works
Lai, C. K. Y. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s63504 · Cited by 136 · see citing works
Capon, D. A., Bochner, F., Kerry, N. L., Mikus, G., Danz, C., & Somogyi, A. A. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90056-9 · Cited by 135 · see citing works
Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology
Fenili, D., Brown, M., Rappaport, R. V., & McLaurin, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0156-7 · Cited by 133 · see citing works
Blanco-Silvente, L., Castells, X., Sáez, M., Barceló, M., Garre-Olmo, J., Vilalta-Franch, J., & Capellà, D. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx012 · Cited by 133 · see citing works
The effects of oxytocin on social cognition and behaviour in frontotemporal dementia
Jesso, S., Morlog, D., Ross, S., Pell, M. D., Pasternak, S., Mitchell, D. G. V., KERTESZ, A. E., & Finger, E. C. (2011) · Brain · doi:10.1093/brain/awr171 · Cited by 129 · see citing works
Woodward, M. R., Harper, D. G., Stolyar, A., Forester, B. P., & Ellison, J. M. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.11.022 · Cited by 128 · see citing works
Zhang, X., Heng, X., Li, T., Li, L., Yang, D., Zhang, X., Du, Y., Doody, R. S., & Le, W. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101875 · Cited by 117 · see citing works
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113 · see citing works
Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review
Masopust, J., Protopopová, D., Vališ, M., Pavelek, Z., & Klímová, B. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s163842 · Cited by 113 · see citing works
Padala, P. R., Padala, K. P., Lensing, S., Ramirez, D., Monga, V., Bopp, M. M., Roberson, P. K., Dennis, R. A., Petty, F., Sullivan, D. H., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030316 · Cited by 112 · see citing works
Shelef, A., Barak, Y., Berger, U., Paleacu, D., Tadger, S., Plopski, I., & Baruch, Y. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150915 · Cited by 107 · see citing works
Yu, F., Zhang, Y., & Chuang, D. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2012.2449 · Cited by 103 · see citing works
Oxytocin for frontotemporal dementia
Finger, E. C., MacKinley, J. D., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., BORRIE, M. J., Wells, J., Dziobek, I., Pasternak, S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001133 · Cited by 102 · see citing works
Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033693 · Cited by 102 · see citing works
Alexopoulos, G. S., Jeste, D. V., Chung, H., Carpenter, D., ROSS, R. W., & Docherty, J. P. (2005) · PubMed · Cited by 99 · see citing works
Methylphenidate for Apathy and Functional Status in Dementia of the Alzheimer Type
Padala, P. R., Burke, W. J., Shostrom, V., Bhatia, S. C., Wengel, S. P., POTTER, J. F., & Petty, F. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181cabcf6 · Cited by 98 · see citing works
Moore, A. E., Patterson, C., Lee, L. S., Vedel, I., & Bergman, H. (2014) · Europe PMC (PubMed Central) · Cited by 93 · see citing works
Tambaro, S., & Bortolato, M. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842269 · Cited by 89 · see citing works
Barak, Y., Plopski, I., Tadger, S., & Paleacu, D. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000743 · Cited by 87 · see citing works
Das, S., Barnwal, P., Aruldhas, B. W., Mondal, S., & Saha, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315614739 · Cited by 84 · see citing works
Walther, S., Schüpbach, B., Seifritz, E., Homan, P., & Strik, W. K. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e861c · Cited by 83 · see citing works
Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort
Gonfrier, S., Andrieu, S., David, R., Vellas, B. J., & Robert, P. (2011) · The journal of nutrition health & aging · doi:10.1007/s12603-011-0147-9 · Cited by 74 · see citing works
The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation
Findling, R. L., Frazier, J. A., Kafantaris, V., Kowatch, R. A., McClellan, J., Pavuluri, M. N., Sikich, L., Hlastala, S. A., Hooper, S. R., Demeter, C., et al. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-21 · Cited by 67 · see citing works
Lanctôt, K. L., Herrmann, N., van Reekum, R., Eryavec, G. M., & Naranjo, C. A. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.636 · Cited by 66 · see citing works
Katsouri, L., Vizcaychipi, M. P., McArthur, S., Harrison, I. F., Suárez‐Calvet, M., Lleó, A., Lloyd, D. G., Ma, D., & Sastre, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.010 · Cited by 66 · see citing works
The Economic Impact of Neuropsychiatric Symptoms in Alzheimer???s Disease
Murman, D. L., & Colenda, C. C. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523030-00004 · Cited by 64 · see citing works
Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
Liu, C. S., Chau, S. A., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2015) · CNS Drugs · doi:10.1007/s40263-015-0270-y · Cited by 63 · see citing works
Ho, T., Pollock, B. G., Mulsant, B. H., Schantz, O., Devanand, D., Mintzer, J. E., Porsteinsson, A. P., Schneider, L. S. S., Weintraub, D. A., Yesavage, J. A., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12997 · Cited by 61 · see citing works
AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type
Garay, R. P., & Grossberg, G. T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267726 · Cited by 58 · see citing works
Central Serotonergic Activity is Related to the Aggressive Behaviors of Alzheimer's Disease
Lanctôt, K. L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00339-1 · Cited by 55 · see citing works
Prommer, E. (2011) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909111427029 · Cited by 51 · see citing works
Devshi, R., Shaw, S., Elliott‐King, J., Hogervorst, E., Hiremath, A., Velayudhan, L., Kumar, S., Baillon, S. F., & Bandelow, S. (2015) · Diagnostics · doi:10.3390/diagnostics5040564 · Cited by 47 · see citing works
Çakır, S. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3201 · Cited by 41 · see citing works
Advancements in the treatment of agitation in Alzheimer’s disease
Antonsdottir, I. M., Smith, J. S., Keltz, M., & Porsteinsson, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059422 · Cited by 40 · see citing works
Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Diefenderfer, L. A., & Iuppa, C. A. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.207 · Cited by 40 · see citing works
Scherer, R. W., Drye, L. T., Mintzer, J. E., Lanctôt, K. L., Rosenberg, P. B., Herrmann, N., Padala, P. R., Brawman‐Mintzer, O., Burke, W. J., Craft, S., et al. (2018) · Trials · doi:10.1186/s13063-017-2406-5 · Cited by 39 · see citing works
Vaingankar, J. A., Chong, S. A., Abdin, E., Picco, L., Jeyagurunathan, A., Seow, E., Ng, L. L., Prince, M. J., & Subramaniam, M. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217000564 · Cited by 38 · see citing works
Cruz, M. P. (2017) · PubMed Central · Cited by 38 · see citing works
Shock-induced aggression in mice is modified by lithium
Kovacsics, C. E., & Gould, T. D. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.09.020 · Cited by 37 · see citing works
Behavioral Syndromes in Mild Cognitive Impairment and Alzheimer's Disease
der Mussele, S. V., Mariën, P., Saerens, J., Somers, N., Goeman, J., Deyn, P. P. D., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130596 · Cited by 34 · see citing works
The effect of lithium administration in animal models of depression: a short review
Redrobe, J. P., & Bourin, M. (1999) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1999.tb00348.x · Cited by 32 · see citing works
Rating Scales for Depression in the Elderly
Kørner, A., Lauritzen, L., Abelskov, K. E., Gulmann, N. C., Brodersen, A. M., Wedervang-Jensen, T., & Kjeldgaard, K. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0305 · Cited by 31 · see citing works
Herrmann, N., Lanctôt, K. L., Eryavec, G. M., & Khan, L. R. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042625 · Cited by 27 · see citing works
Viscogliosi, G., Chiriac, I. M., & Ettorre, E. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.06.010 · Cited by 27 · see citing works
Growth hormone response to clonidine predicts aggression in Alzheimer’s disease
Herrmann, N., Lanctôt, K. L., Eryavec, G. M., van Reekum, R., & Khan, L. R. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.02.001 · Cited by 25 · see citing works
on behalf of the PICTURE Study Group, Gensichen, J. S., Schultz, S., Adrion, C., Schmidt, K. F. R., Schauer, M., Lindemann, D., Unruh, N., Kosilek, R. P., Schneider, A., et al. (2018) · Trials · doi:10.1186/s13063-018-2853-7 · Cited by 25 · see citing works
Psychometric Properties of Apathy Scales in Dementia: A Systematic Review
Mohammad, D., Ellis, C., Rau, A., Rosenberg, P. B., Mintzer, J. E., Ruthirakuhan, M. T., Herrmann, N., & Lanctôt, K. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180485 · Cited by 25 · see citing works
Wu, E. Q., Greenberg, P. E., Yang, E., Yu, A., & Erder, M. H. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802303525 · Cited by 23 · see citing works
Al‐Majed, A. A., Bakheit, A. H. H., Alharbi, R. M., & Abdel‐Aziz, H. A. (2018) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/bs.podrm.2018.01.002 · Cited by 23 · see citing works
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia
Wilkins, J. M., & Forester, B. P. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0656-z · Cited by 19 · see citing works
Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia
Sherman, C., Ruthirakuhan, M. T., Vieira, D., Lanctôt, K. L., & Herrmann, N. (2017) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000399 · Cited by 19 · see citing works
Vanover, K. E., Dmitrienko, A. A., Glass, S., Kozauer, S. G., Saillard, J., Weingart, M., Satlin, A., Mates, S. L., Correll, C. U., & Davis, R. E. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby018.831 · Cited by 17 · see citing works
Music lives on: fine tuning the memory
Morgan, J. D. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30399-x · Cited by 12 · see citing works
The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist
Zhang, L., & Hendrick, J. P. (2018) · Matters · doi:10.19185/matters.201712000006 · Cited by 8 · see citing works
Cummings, J. L., Lyketsos, C. G., Tariot, P. N., Peskind, E. R., Nguyen, U., Knowles, N., Shin, P., & Siffert, J. O. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.12.171 · Cited by 7 · see citing works
Pull, C. B., & Janča, A. (2017) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000384 · Cited by 7 · see citing works
Effect of carbamazepine on agitation and emotional lability associated with severe dementia
Mr, L. (1995) · European Psychiatry · doi:10.1016/0924-9338(96)80303-8 · Cited by 6 · see citing works
Forester, B. P., Romano, C., Quayle, W., Georgakas, J. E., & Rosenberg, P. B. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.1839 · Cited by 6 · see citing works
Citalopram-induced QTc prolongation: A brief review of the data
Tran, E., & Dishman, B. R. (2012) · Mental Health Clinician · doi:10.9740/mhc.n129018 · Cited by 5 · see citing works
Lanctôt, K. L., Ruthirakuhan, M. T., Gallagher, D., Sherman, C., Abraham, E. H., Verhoeff, N. P. L. G., Iaboni, A., Black, S. E., Andreazza, A. C., Kiss, A., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2871 · Cited by 5 · see citing works
Herrmann, N. (2016) · Evidence-Based Mental Health · doi:10.1136/eb-2016-102474 · Cited by 1 · see citing works
P3‐020: The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer’s Disease Subjects
An, H., Choi, B., Park, K.-W., Kim, D., Yang, D. W., Hong, C. H., Kim, S. Y., & Han, S. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.1677 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · see citing works
“EVP-6124 is an α7 nicotinic acetylcholine receptor agonist and a 5-HT3 receptor antagonist and mediates the release of multiple neurotransmitters, such as γaminobutyric acid, glutamate, ACh, and dopamine [78, 79].”
BackgroundAn update on the novel and approved drugs for Alzheimer disease
Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122 · see citing works
“EVP-6124, an antagonist of 5-HT3 receptor and a agonist of 7 nicotinic acetylcholine receptor a has a central role in regulating the release of various neurotransmitters (Ahmed et al., 2019).”
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 110 · see citing works
The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease
Calsolaro, V., Antognoli, R., Okoye, C., & Monzani, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01465 · Cited by 65 · see citing works
Couteur, D. G. L., Hilmer, S. N., Glasgow, N., Naganathan, V., & Cumming, R. G. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg006.pub2 · Cited by 59 · see citing works
Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects
Silva, A. R., & Dinis‐Oliveira, R. J. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1758712 · Cited by 55 · see citing works
Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease
Martins, M., Silva, R., Pinto, M. M. M., & Sousa, E. (2020) · Pharmaceuticals · doi:10.3390/ph13090242 · Cited by 53 · see citing works
The role of lumateperone in the treatment of schizophrenia
Syed, A. B., & Brašić, J. R. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034019 · Cited by 37 · see citing works
Leijenaar, J. F., Groeneveld, G. J., Klaassen, E. S., Leeuwis, A. E., Scheltens, P., Weinstein, H. C., van Gerven, J., Barkhof, F., van der Flier, W. M., & Prins, N. D. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0567-z · Cited by 26 · see citing works
Longo, G., Cicolini, A., Orsolini, L., & Volpe, U. (2023) · Brain Sciences · doi:10.3390/brainsci13121641 · Cited by 19 · see citing works
New Medications for Neuropsychiatric Disorders
Reddy, H. M., Poole, J. S., Maguire, G. A., & Stahl, S. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.008 · Cited by 16 · see citing works
Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic
Sowa-Kućma, M., Pańczyszyn-Trzewik, P., & Jaeschke, R. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413289 · Cited by 14 · see citing works
Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders
Mazza, M., Marano, G., Traversi, G., Sani, G., & Janiri, L. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200601145653 · Cited by 12 · see citing works
Oliveira, L. D. F., Camargos, E. F., Louzada, L. L., Machado, F. V., & Novaes, M. R. C. G. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113591 · Cited by 11 · see citing works
Leme, D. E. D. C., Mathias, K., Mofina, A., Liperoti, R., Betini, G. S., & Hirdes, J. P. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.105255 · Cited by 10 · see citing works
Multi-Target-Directed Ligand Approach in Anti-Alzheimer’s Drug Discovery
Patil, V. M., Masand, N., Gautam, V., Kaushik, S., & Wu, D. H. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_13 · Cited by 8 · see citing works
Potentially Inappropriate Drug Duplication in a Cohort of Older Adults with Dementia
Trenaman, S. C., Bowles, S. K., Kirkland, S., & Andrew, M. K. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100644 · Cited by 8 · see citing works
Sasaki, H., Jono, T., Fukuhara, R., Honda, K., Ishikawa, T., Boku, S., & Takebayashi, M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03978-0 · Cited by 8 · see citing works
Lumateperone: New Drug or Same Old Drug With a New Dress?
Limandri, B. J. (2020) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20200513-01 · Cited by 6 · see citing works
Rashid, N., Wetmore, J. B., Irfan, M., Peng, Y., & Abler, V. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000401 · Cited by 5 · see citing works
Calsolaro, V., Antognoli, R., & Monzani, F. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1641407 · Cited by 2 · see citing works
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg006 · Cited by 2 · see citing works
Drug Discovery from Medicinal Plants against Alzheimer's Disease
Marzouk, M. M., Farid, M. M., Hegazi, N. M., & Ezzat, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch3 · Cited by 4 · see citing works
Muthuraman, A., Ramesh, M., & Kumar, T. V. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-5167-3_6
Are Nurses Prescribing Lumateperone (Caplyta)?
Mills, J. (2021) · Issues in Mental Health Nursing · doi:10.1080/01612840.2021.2003123
Atypical antipsychotic Lumateperone Beyond Schizophrenia: Seeking clarity in a time of UncertaintyPreprint
Mohamed, W. M. Y. (2022) · doi:10.31730/osf.io/26xec
Chapter 24. Clinical Psychiatry in the Nursing Home
Lantz, M., Blissett, K.-A., & Streim, J. E. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds24
Atypical antipsychotic lumateperone beyond schizophrenia: Seeking clarity in a time of uncertainty
Mohamed, W. M. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00028-2
Swain, S., & Metya, A. K. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00456
- Authors
- Ahmed, M., Malik, M., Teselink, J., Lanctôt, K. L., & Herrmann, N.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Herrmann, Nathan
- Venue
- Drugs & Aging
- Published
- 2019-04-08
- Volume
- 36
- Issue
- 7
- Pages
- 589-605
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- OpenAlex
- W2936337273
- Cited by
- 29
- References
- 112
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 9 · 2019: 2
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- behavioral and psychological symptoms of dementia, clinical trials, dextromethorphan/quinidine, lumateperone, atypical antipsychotics, selective serotonin reuptake inhibitors, cannabinoids, drug safety and tolerability, dementia treatment
- MeSH terms
- Drug Development, Animals, Behavior, Cannabinoids, Cholinesterase Inhibitors, Dementia, Humans, Antipsychotic Agents, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
